Lifeboat Foundation

For the more than 1 million Americans who live with type 1 diabetes, daily insulin injections are literally a matter of life and death. And while there is no cure, a Cornell University-led research team has developed a device that could revolutionize management of the disease.

In Type 1 diabetes, insulin-producing pancreatic cell clusters (islets) are destroyed by the body’s immune system. The research group, led by assistant professor Minglin Ma from the Department of Biological and Environmental Engineering, has devised an ingenious method for implanting hundreds of thousands of islet cells into a patient. They are protected by a thin hydrogel coating and, more importantly, the coated cells are attached to a polymer thread and can be removed or replaced easily when they have outlived their usefulness.

Transplantation of stem cell-derived, insulin-producing islet cells is an alternative to insulin therapy, but that requires long-term immunosuppressive drug administration. One well-researched approach to avoid the immune system’s response is to coat and protect the cells in tiny hydrogel capsules, hundreds of microns in diameter. However, these capsules cannot be taken out of the body easily, since they’re not connected to each other, and there are hundreds of thousands of them.

Continue reading “Spider’s web inspires removable implant that may control type 1 diabetes” »

http://www.trtrevolution.com/age-reversal-life-extension-eli…ra-pastor/

Summary: Biomarkers of aging would be a breakthrough that slashes the time and cost it currently takes to develop lifespan-extension drugs. [Author: Brady Hartman. This article first appeared on the LongevityFacts.com website. ]

Biomarkers of aging would revolutionize the development of lifespan-extension drugs, helping to bring them out of the laboratory and into the clinic in a fraction of the time and at a fraction of the cost. The first scientist to come up with an effective biomarker of aging would produce a true breakthrough for the field of life extension.

Imagine that geroscientists have just developed a miraculous compound called Regulus that promises to extend human lifespans by a significant amount. Unfortunately, the researchers would not have an easy time testing Regulus because humans live a long time. Testing Regulus in mice, would help, but researchers would still have to test the drug’s lifespan-extending effects in humans. Before anti-aging physicians could prescribe Regulus, it would need to undergo an expensive and lengthy clinical trial.

Continue reading “We Need Breakthrough Biomarkers of Aging to Revolutionize Lifespan Extension” »

Summary: These breakthroughs in stem cell therapy could potentially rejuvenate our damaged organs with induced pluripotent stem cells (iPSCs). Moreover, biotech firms are rushing to bring organ-rejuvenating cell therapies to the marketplace. [This article first appeared on the LongevityFacts.com website. Author: Brady Hartman. ]

Recent advances in stem cell therapies could translate into effective treatments for intractable diseases.

Stem cells are the repairmen of our bodies. Unlike our ordinary cells, stem cells can divide without limit and create fresh copies of nearly any tissue type to repair damaged organs. While we have an abundance of these repairmen in our youth, we experience stem cell decline as we age.

Continue reading “Breakthroughs Set To Revolutionize Stem Cell Therapy” »

Researchers find promising Alzheimer’s treatment with a diabetes drug that ‘significantly reversed memory loss.’

Promising alzheimer’s treatment using diabetes drug.

Scientists announced a drug that ‘significantly reversed memory loss’ in mice with Alzheimer’s disease.

Continue reading “(Video) Researchers Find Promising Alzheimer’s Treatment Using Diabetes Drug” »

Mesenchymal stem cells (MSCs) are one of the most thoroughly studied and understood stem cell types. They are used in a wide range of therapies, and the many studies using MSCs have enjoyed varied levels of success, depending on delivery methods, patients, co-therapies and other factors.

Today, we will be taking a look at MSCs and a new human clinical trial focused on treating osteoarthritis, an age-related inflammatory condition that leads to the breakdown of bone and cartilage.

Victor Björk, biologist and member of the LEAF teama report about a recent aging research conference that he attended in Germany. Victor is one of our more well-traveled writers, and he has the fortune to attend many interesting shows, events, and conferences in Europe. Today Victor reports on the DGfA Aging Conference and also interviews James Peyer from Apollo Ventures, an early-stage life science investor and company builder focused on translational research for age-related diseases.

An annual aging research conference

I took part in the yearly DGfA conference at the Max Planck Institute for Aging Research in Cologne on December 1–2, 2017. The event was organized by the German association for aging research, an interdisciplinary non-profit organization based in Nürnberg. Established in 1990, it conducts research on aging, including research on developing therapeutic options to treat age-related diseases.

Dental hygiene options are looking a little brighter.

Scientists from Rice University have discovered a titanium alloy that’s better than titanium at being a medical implant, and it is four times harder than titanium and a vast majority of steels.

When it comes to bone replacements, the go-to material is still titanium. Hard, wear-resistant, and compatible to the body, titanium looks like the best alternative to actual bone, maybe even better. Who knew that you could improve the ‘gold standard’ by just adding actual gold?